HealthEquity (HQY)
(Delayed Data from NSDQ)
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Zacks News
HealthEquity (HQY) Surpasses Q2 Earnings Estimates, FY24 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the second quarter of fiscal 2024.
Why You Should Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Revvity (RVTY) Launches Three New Preclinical Research Systems
by Zacks Equity Research
Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.
Compared to Estimates, HealthEquity (HQY) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended July 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HealthEquity (HQY) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 12.77% and 1.95%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain PacBio (PACB) Stock for Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany
by Zacks Equity Research
DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.
NextGen's (NXGN) Shares Rise on Potential Acquisition Rumors
by Zacks Equity Research
NextGen (NXGN) and a private equity firm, Thomas Bravo, are in advanced stages of discussion related to the acquisition of the former by the latter.
Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation
by Zacks Equity Research
Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.
Is HealthEquity (HQY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and InMode (INMD) have performed compared to their sector so far this year.
Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool
by Zacks Equity Research
Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Masimo's (MASI) Inks Agreement to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.
Veeva (VEEV) Rises on Robust Earnings: More Room to Grow?
by Zacks Equity Research
Veeva (VEEV) reports better-than-expected earnings and revenues for the second quarter. The raised earnings outlook for fiscal 2024 reflects optimism. Will the uptrend in shares continue?
Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod
by Zacks Equity Research
Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.
Cardinal Health's (CAH) Latest Launch to Enhance Neonatal Feeding
by Zacks Equity Research
Cardinal Health's (CAH) latest offering is likely to help premature and newborn infants develop the oral coordination skills important for the faster transition to independent feeding.
Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH
by Zacks Equity Research
Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.
Patterson Companies (PDCO) Q1 Earnings In Line, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) first-quarter fiscal 2024 results reflect robust improvement in Dental Equipment sales, value-added services and Animal Health segment.
Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report
by Zacks Equity Research
Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
STERIS (STE) Banks on New Pact for Growth Amid Rising Expenses
by Zacks Equity Research
Continuous procedure volume growth in the United States, favorable pricing and market share gains are driving STERIS' (STE) Healthcare segment organic growth.
Haemonetics (HAE) Expands VASCADE System Portfolio in Germany
by Zacks Equity Research
Haemonetics (HAE) announces the first treatment of patients in Germany with the VASCADE MVP Venous Vascular Closure system.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners
by Zacks Equity Research
Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
3 Medical Services Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.